Physician

Suresh Ratnam, MD

According to 2025 Medicare claims, Suresh Ratnam, MD (NPI: 1649217639) practices medical oncology in the McAllen-Edinburg-Mission, TX market, with the plurality of this provider's patient population coming from Hidalgo, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 78503-1271.

Ratnam's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 373 traditional Medicare patients, billed 41,527 HCPCS/CPT codes, and received $737,655 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,004 prescription claims across 251 beneficiaries totaling $4,218,893 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 28 claims. Open Payments data shows 349 records totaling $525,161. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,554,602 to $737,655. In contrast, Part D prescription costs have moved sharply higher in recent years, from $733,565 to $4,218,893. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $1,764 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	395	223,430	$1,554,602
2016	491	127,212	$1,148,022
2017	512	45,150	$687,404
2018	448	35,033	$648,999
2019	457	47,969	$781,556
2020	430	31,081	$818,948
2021	421	22,703	$638,167
2022	415	20,924	$425,577
2023	422	39,697	$751,316
2024	373	41,527	$737,655

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	101	471	$733,565
2016	96	482	$1,025,385
2017	128	633	$1,089,242
2018	126	701	$1,274,485
2019	165	811	$1,685,417
2020	201	1,273	$2,846,095
2021	214	979	$2,904,103
2022	230	1,101	$4,328,767
2023	253	1,110	$4,179,153
2024	251	1,004	$4,218,893

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	92	$23,588
2016	11	94	$5,935
2017	13	101	$4,275
2018	11	21	$1,764
2019	N/R	28	$1,662
2020	N/R	28	$1,678
2021	N/R	42	$14,148
2022	N/R	43	$1,181
2023	N/R	28	$3,414
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	194	441	$90
80053	Blood test, comprehensive group of blood chemicals	196	687	$10
36415	Insertion of needle into vein for collection of blood sample	224	914	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	219	859	$8
83615	Lactate dehydrogenase (enzyme) level	137	546	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	82	2,002	$1,246,090
Xtandi	Enzalutamide	30	900	$398,151
Verzenio	Abemaciclib	23	644	$355,934
Inlyta	Axitinib	14	420	$281,967
Imbruvica	Ibrutinib	13	420	$229,774

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	344	$490,034	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$35,127	Aadi Bioscience, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Suresh Ratnam, MD?

Tedicare shows public-source Medicare data for Suresh Ratnam, MD (NPI 1649217639), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Suresh Ratnam, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Suresh Ratnam, MD?

Suresh Ratnam, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Suresh Ratnam, MD have Open Payments data?

Suresh Ratnam, MD has 349 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.